Search results
Your search for cost benefrt of cancer drugs returned no results
Showing 1 to 15 of 466 results for cost benefit of cancer drugs
Showing 1 to 15 of 466 results for cost benefit of cancer drugs
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Low back pain and sciatica in over 16s: assessment and management (NG59)
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults.
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer (TA100)
Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer in adults.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.